SCHEMBL9997159

SCHEMBL9997159

O=C(O)c1ccc(NS(=O)(=O)c2cc(F)ccc2F)cc1O

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.62
HPGD P15428 2/20 0.62
ALDH1A1 P00352 3/20 0.61
PFKFB3 Q16875 3/20 0.58
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
USP2 O75604 1/20 0.55
TSHR P16473 1/20 0.55
FABP4 P15090 6/20 0.54
FABP5 Q01469 4/20 0.54
PTK2B Q14289 1/20 0.51
MCL1 Q07820 1/20 0.51
ACLY P53396 1/20 0.49
BRD4 O60885 1/20 0.48
PYGL P06737 1/20 0.47
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9997155 0.88 HSD17B10 (0.79) HSD17B10HPGDALDH1A1PFKFB3MEN1
SCHEMBL9997334 0.87 ALDH1A1 (0.73) HSD17B10HPGDALDH1A1PFKFB3MEN1
SCHEMBL19281319 0.85 HSD17B10 (0.66) HSD17B10HPGDALDH1A1PFKFB3MEN1
SCHEMBL9997171 0.82 ALDH1A1 (0.58) HSD17B10HPGDALDH1A1PFKFB3MEN1
SCHEMBL19281324 0.82 HSD17B10 (0.66) HSD17B10HPGDALDH1A1PFKFB3MEN1
SCHEMBL19281351 0.82 ALDH1A1 (0.58) HSD17B10HPGDALDH1A1PFKFB3MEN1
SCHEMBL9997053 0.81 PFKFB3 (0.70) HSD17B10HPGDALDH1A1PFKFB3FABP4
SCHEMBL9996904 0.81 PFKFB3 (0.74) HSD17B10HPGDALDH1A1PFKFB3MEN1
SCHEMBL9997248 0.80 MCL1 (0.62) HSD17B10HPGDALDH1A1PFKFB3MEN1
SCHEMBL9997432 0.79 PFKFB3 (0.58) HSD17B10HPGDALDH1A1PFKFB3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed
WO-2011161201-A1 BISARYLSULFONAMIDES USEFUL AS KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATION AND CANCER KANCERA AB (SE) 2011-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 HSD17B10 1255/4885HPGD 980/4885ALDH1A1 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.